UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
Does Congress or the president hold war powers? Here’s what to know
President Trump's decision to launch airstrikes on Iran's nuclear facilities without first consulting Congress has drawn sharp criticism from lawmakers who say the move bypasses their constitutional authority to declare war.
U.S. Supreme Court allows — for now — third-country deportations
A federal judge had previously said people must get at least 15 days to challenge their deportations to countries they're not originally from.
Democratic senators rent space at the Kennedy Center to host a Pride event
A group of Democratic senators and Hamilton producer Jeffrey Seller are hosting a Pride celebration at the Kennedy Center Monday evening. But the Kennedy Center has nothing to do with programming it.
What to know about Jeff Bezos’ upcoming Venice wedding — and the protests against it
Bezos will soon marry Lauren Sánchez in Venice. Protesters say the city, already grappling with overtourism, is putting the wedding over their needs — which city officials and wedding organizers deny.
Emmy nominations voting ends tonight. Here’s what our critic hopes will make the cut
Emmy voters have until tonight to send in their picks for nominees. Here's what NPR TV critic Eric Deggans thinks they should be voting for.
Iran attacks a U.S. base in Qatar
A U.S. defense official confirmed that the Al Udeid Air Base in Qatar "was attacked by short-range and medium-range ballistic missiles originating from Iran" and said there were no casualties.
